A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

NCT04951635 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Almonertinib
DRUG: Placebo Almonertinib

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.